Palbociclib Shows Promise for Treatment of Brain Metastases Harboring CDK Alterations
November 24th 2019An interim analysis of the phase II study of palbociclib for the treatment of patients with brain metastases harboring CDK alterations was presented at the 2019 Society for NeuroOncology Annual Meeting by Priscilla K. Brastianos, MD, director of the central nervous system brain metastasis program, Massachusetts General Hospital.<br />
Watch
Rucaparib May Improve PFS in Patients With Ovarian Cancer
November 22nd 2019Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.
Watch
Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk Myelofibrosis
November 22nd 2019Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br />
Watch
Age Impacts Treatment Options for Patients With CLL
November 21st 2019Kanti R. Rai, MD, professor of medicine, Northwell Health and Zucker School of Medicine at Hofstra University, explains the importance of attention to age when treating patients with chronic lymphocytic leukemia, which is a typically elderly patient population.
Watch